Please assess the completion status of the following clinical trial:

Trial Title: Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient (e) Age (e) over 18 years~* Kidney cancer metastatic or locally advanced~* Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together~* Proposed treatment in first line or second line~* Brain imaging not finding brain metastases~* Having signed the informed consent of study participation~* The patient may have received prior anti-angiogenic~Exclusion Criteria:~* Cancer of the kidney other than primitive~* Previous history of cancer other than kidney cancer in complete remission for less than 5 years~* Patients under 18 years~* Patients whose treatment is associated with chemotherapy~* disorders of cognitive functions to existing treatment delivery~* Pathology psychiatric evolutionary~* Refusal of participation~* Patient unable to respond to cognitive tests~* Drug use~* Heavy drinking (WHO criteria)~* History of stroke~* History of head trauma~* Brain metastases known~* MMS below normal compared to existing standards for age and socio-cultural

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients group (Type: None): Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic

Based on this trial design, predict the completion outcome and termination type (if applicable).